No adverse events were observed in clozapine‐treated patients on extended hematologic monitoring intervals during the coronavirus pandemic in four psychiatric centers in Japan

• Main Authors: Masahiro Hata (Author), Michiko Fujimoto (Author), Koji Kanai (Author), Kenji Yoshiyama (Author), Yoshitaka Nakatani (Author), Daiji Nakabayashi (Author), Saki Maemura (Author), Shinya Kawata (Author), Takaaki Hakozaki (Author), Shuya Nishikura (Author), Aiko Umemoto (Author), Toru Sasada (Author), Kazuhiko Iwata (Author), Hideki Tanaka (Author), Akiko Mamoto (Author), Yuuki Toi (Author), Norio Taniguchi (Author), Makiko Saito (Author), Yoshio Kimura (Author), Kazuko Kishimoto (Author), Megumi Hayami (Author), Manabu Ikeda (Author)
• Format: Book
• Published: Wiley, 2021-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Aim As an emergency measure during the coronavirus disease pandemic, the monitoring interval for clozapine use was temporarily extended beyond the regulatory requirement in Japan, which is the safest monitoring interval worldwide. In this study, we aimed to explore the effect of this measur...